Alamar Biosciences, Inc. · NASDAQ (us_market)
Healthcare · Medical Devices · United States
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. The company was incorporated in 2018 and is based in Fremont, California.
No qualifying bottom-picking events since 2020.
No scored news yet for a sentiment trend.
What Alamar Biosciences stock is telling you right now Alamar Biosciences (ALMR) has attracted fresh attention after recent trading left the stock with a last close of US$23.01 and a year to date gain of 4.59%, against mixed shorter term returns. For context, the stock was roughly flat over the past day, gained 0.17%, but declined 3.48% over the past week. Month and past 3 months performance data is not available, so short term momentum beyond these windows is harder to compare. See our...
Toast downgraded, Lowe's upgraded: Wall Street's top analyst calls
Analysts change outlook on top names. Check their ratings & price targets for AVEX, ALMR, TNDM, SWX, KLRA. See what they think of SWX stock.
TD Cowen analyst Dan Brennan initiates coverage on Alamar Biosciences (NASDAQ:ALMR) with a Buy rating and announces Price Target of $30.
JP Morgan analyst Casey Woodring initiates coverage on Alamar Biosciences (NASDAQ:ALMR) with a Overweight rating and announces Price Target of $30.
Stifel analyst Daniel Arias initiates coverage on Alamar Biosciences (NASDAQ:ALMR) with a Buy rating and announces Price Target of $28.
Alamar Biosciences (NASDAQ:ALMR) reported quarterly losses of $(1.74) per share. The company reported $26.035 million in sales this quarter.
FREMONT, Calif., May 08, 2026 -- Alamar Biosciences, Inc. , a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the...
Alamar Biosciences surged 30% post-IPO, driven by enthusiasm for its precision proteomics technology targeting early disease detection. Read more on ALMR stock here.
Alamar Biosciences, Inc.âs $100M IPO aims to scale protein biomarker diagnostics as revenue jumps 195%. Click for this first look at the ALMR stock offering
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ALMR | -20.81% | — | — | — |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -23.78% | — | — | — |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | — | — | — |